Athanasios Zomas

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.

A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.

Journal: Advances in therapy
Published: January 28, 2026

Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma.

Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma.

Journal: Future oncology (London, England)
Published: January 12, 2026

Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.

Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.

Journal: Bone marrow transplantation
Published: December 20, 2024

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Journal: Lancet (London, England)
Published: June 06, 2024

A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.

A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.

Journal: Cancers
Published: October 19, 2023

First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes.

First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes.

Journal: EJHaem
Published: December 13, 2021

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries.

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries.

Journal: Cancers
Published: November 26, 2021

Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.

Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.

Journal: Leukemia & lymphoma
Published: July 29, 2021

Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.

Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.

Journal: Expert review of hematology
Published: August 05, 2020

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Journal: Annals of hematology
Published: December 08, 2019

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Journal: British journal of haematology
Published: May 24, 2019

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.

Journal: European journal of haematology
Published: June 29, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026